Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Swedish Medical Center
• Collaborator: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Bronchoalveolar carcinoma with disease measurable on CAT scan

• Any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with disease measurable on CAT scan

• Stage IIIB or IV

Exclusion Criteria:

• Uncontrolled hypertension

• Unstable brain metastases

• Pregnant/nursing women

• Uncontrolled thyroid disease